**Comment:**
The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which the sample was run met all assay specific quality metrics.

175 genes were targeted covering 2470 unique coding hot spots, 281 fusions and 19 CNV genes for actionable mutations linked to 484 anti-cancer targeted therapies.

The following actionable mutations were detected. Considering the cancer is of an unknown origin, this report encompasses the entire scope of linkages for the below variants. Please note that some of the linkages to clinical trials are tumour type specific.

### Variant Summary

**Sample Cancer Type:** Cancer of unknown primary

<table>
<thead>
<tr>
<th>Gene Variant</th>
<th>EMA</th>
<th>US-FDA</th>
<th>ESMO</th>
<th>US-NCCN</th>
<th>Global Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET amplification</td>
<td>Δ</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>(1) (30)</td>
</tr>
<tr>
<td>MET(13)-MET(15) exon 14 skipping</td>
<td>Δ</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>(1) (8)</td>
</tr>
<tr>
<td>CDK6 amplification</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>(2)</td>
</tr>
</tbody>
</table>

**EMA:** European Medicine Agency, **US-FDA:** United States-Food and Drug Administration, **ESMO:** European Society for Medical Oncology, **US-NCCN:** United States-National Comprehensive Cancer Network. Numbers in parentheses indicate the number of relevant therapies with evidence. Hotspot variants with >10% alternate allele reads, and in >10 unique reads are classified as ‘detected’. Copy number variants of a >5% confidence value of ≥4 after normalisation are classified as amplified. Gene Fusions are reported when occurring in >20 counts and meeting the thresholds of assay specific internal RNA quality control. Assay sensitivity and positive predictive value is 99% when these thresholds are met. Supplementary technical information is available upon request.

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

**Disclaimer:** The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### Relevant Therapy Summary

#### MET amplification

<table>
<thead>
<tr>
<th>Relevant Therapy</th>
<th>EMA</th>
<th>US-FDA</th>
<th>ESMO</th>
<th>US-NCCN</th>
<th>Clinical Trials*</th>
</tr>
</thead>
<tbody>
<tr>
<td>crizotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☑</td>
<td>(I)</td>
</tr>
<tr>
<td>erlotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(IV)</td>
</tr>
<tr>
<td>alpelisib, binimetinib, capmatinib, ceritinib, luminespib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>capmatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>capmatinib + nivolumab, EGF-816 + nivolumab</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>erlotinib + chemotherapy</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>MGCD-265</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>SAR-125844</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>gefitinib + tepotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I/II)</td>
</tr>
<tr>
<td>altiratinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>capmatinib + erlotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>crizotinib + chemotherapy, crizotinib + pazopanib, crizotinib + pazopanib + chemotherapy</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>crizotinib + dasatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>gefitinib + volitinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>MGCD-516</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>volitinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>bevacizumab + capmatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>volitinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
<tr>
<td>volitinib + chemotherapy</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I/II)</td>
</tr>
<tr>
<td>crizotinib + PD-0325901</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(I)</td>
</tr>
</tbody>
</table>

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available. See global clinical trials section in the pages to follow.

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.

DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### MET-MET fusion

<table>
<thead>
<tr>
<th>Relevant Therapy</th>
<th>EMA</th>
<th>US-FDA</th>
<th>ESMO</th>
<th>US-NCCN</th>
<th>Global Clinical Trials*</th>
</tr>
</thead>
<tbody>
<tr>
<td>crizotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>capmatinib + nivolumab, EGF-816 + nivolumab</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(II)</td>
</tr>
<tr>
<td>altiratinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>gefitinib + volitinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>MGCD-265</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>MGCD-516</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>crizotinib + PD-0325901</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>bevacizumab + capmatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(I)</td>
</tr>
<tr>
<td>crizotinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(II)</td>
</tr>
<tr>
<td>buparlisib + capmatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(II)</td>
</tr>
</tbody>
</table>

### CDK6 amplification

<table>
<thead>
<tr>
<th>Relevant Therapy</th>
<th>EMA</th>
<th>US-FDA</th>
<th>ESMO</th>
<th>US-NCCN</th>
<th>Global Clinical Trials*</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZD4547 + chemotherapy, durvalumab, erlotinib, erlotinib + rilotumumab, palbociclib, taselisib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II/III)</td>
</tr>
<tr>
<td>ribociclib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>(II)</td>
</tr>
<tr>
<td>buparlisib + capmatinib</td>
<td>☒</td>
<td>☒</td>
<td>☒</td>
<td>✓</td>
<td>(II)</td>
</tr>
</tbody>
</table>

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available. See global clinical trials section in the pages to follow.
Current US-NCCN Information

- In this cancer type
- In other cancer type
- In this cancer type and other cancer types
- Contraindicated


**MET amplification**

- crizotinib

  - **Cancer type:** Non-Small Cell Lung Cancer
  - **Variant class:** MET amplification

  US-NCCN Recommendation category: 2A

  Population segment (Line of therapy):
  - NSCLC (Not specified)


**MET-MET fusion**

- crizotinib

  - **Cancer type:** Non-Small Cell Lung Cancer
  - **Variant class:** MET exon 14 skipping mutation

  US-NCCN Recommendation category: 2A

  Population segment (Line of therapy):
  - NSCLC (Not specified)


Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.

DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### MET amplification

<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Study Details</th>
<th>Other Identifiers</th>
<th>Population Segments</th>
<th>Phase</th>
<th>Therapy</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01523340</td>
<td>Phase IV Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib</td>
<td>MENTOR, MENTOR_2011, TrialTroveID-161434</td>
<td>EGFR, Second line or greater/Refractory/Relapsed, Stage IV</td>
<td>IV</td>
<td>erlotinib</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>NCT02276027</td>
<td>A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</td>
<td>CINC280X2205, CTR20140725, TrialTroveID-209048</td>
<td>Adenocarcinoma, ALK, EGFR, KRAS, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td>II</td>
<td>alpelisib, binimetinib, capmatinib, ceritinib, luminespib</td>
<td>China</td>
</tr>
<tr>
<td>NCT02414139</td>
<td>A Phase II, Multicenter, Three-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease</td>
<td>CINC280A2201, EudraCT Number: 2014-003850-15, TrialTroveID-255286</td>
<td>Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td>II</td>
<td>capmatinib</td>
<td>Lebanon, Singapore</td>
</tr>
</tbody>
</table>

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.

DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### MET amplification (continued)

<table>
<thead>
<tr>
<th>NCT02034981</th>
<th><strong>AcSé CRIZOTINIB</strong>: Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer type</strong>: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma, Kidney Cancer, Liver Cancer, Non-Small Cell Lung Cancer,</td>
<td><strong>Variant class</strong>: MET amplification</td>
</tr>
<tr>
<td><strong>Other identifiers</strong>: AcSé, AcSé CRIZOTINIB, EudraCT Number: 2013-000885-13, FSCA-crizotinib, TrialTroveID-200633, UC-0105/1303</td>
<td></td>
</tr>
<tr>
<td><strong>Population segments</strong>: Aggressive, Anaplastic, Follicular, Line of therapy N/A, Medullary, Papillary, Pediatric or Adolescent, Peripheral T-cell lymphoma (PTCL), Stage III, Stage IV</td>
<td></td>
</tr>
<tr>
<td><strong>Exclusion criteria variant class</strong>: ALK fusion</td>
<td></td>
</tr>
<tr>
<td><strong>Phase</strong>: II</td>
<td></td>
</tr>
<tr>
<td><strong>Therapy</strong>: crizotinib</td>
<td></td>
</tr>
<tr>
<td><strong>Country</strong>: France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02499614</th>
<th><strong>Crizotinib</strong> in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer type</strong>: Non-Small Cell Lung Cancer</td>
<td><strong>Variant class</strong>: MET amplification</td>
</tr>
<tr>
<td><strong>Other identifiers</strong>: EudraCT Number: 2014-001263-12, FoRT 01/2014, IEO 189, METROS, TrialTroveID-250290</td>
<td></td>
</tr>
<tr>
<td><strong>Population segments</strong>: Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td></td>
</tr>
<tr>
<td><strong>Phase</strong>: II</td>
<td></td>
</tr>
<tr>
<td><strong>Therapy</strong>: crizotinib</td>
<td></td>
</tr>
<tr>
<td><strong>Country</strong>: Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02098954</th>
<th><strong>Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer type</strong>: Non-Small Cell Lung Cancer</td>
<td><strong>Variant class</strong>: MET amplification</td>
</tr>
<tr>
<td><strong>Other identifiers</strong>: TKIRR001, TrialTroveID-205762</td>
<td></td>
</tr>
<tr>
<td><strong>Population segments</strong>: Adenocarcinoma, EGFR, Large Cell, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td></td>
</tr>
<tr>
<td><strong>Phase</strong>: II</td>
<td></td>
</tr>
<tr>
<td><strong>Therapy</strong>: erlotinib + chemotherapy</td>
<td></td>
</tr>
<tr>
<td><strong>Country</strong>: China</td>
<td></td>
</tr>
</tbody>
</table>
## MET amplification (continued)

### NCT02544633
Phase II, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

**Cancer type:** Non-Small Cell Lung Cancer  
**Variant class:** MET amplification  

**Other identifiers:** 265-109, TrialTroveID-257006  
**Population segments:** Second line or greater/Refractory/Relapsed, Stage II, Stage III, Stage IV  
**Exclusion criteria variant classes:** EGFR mutation, ALK fusion  
**Phase:** II  
**Therapy:** MGCD-265  
**Country:** United States  
**US States:** CA, MI  
**US Contact:** Mirati Therapeutics Study Locator Services [844-356-0895; miratistudylocator@emergingmed.com]

### NCT02435121
Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients With Advanced Pretreated Non-Small Cell Lung Cancer (NSCLC) Harboring MET Gene Amplification

**Cancer type:** Non-Small Cell Lung Cancer  
**Variant class:** MET amplification  

**Other identifiers:** ACT14205, EudraCT Number: 2014-005696-93, TrialTroveID-257010, U1111-1163-1136  
**Population segments:** Second line or greater/Refractory/Relapsed, Stage IV  
**Phase:** II  
**Therapy:** SAR-125844  
**Countries:** Australia, Belgium, Bulgaria, Canada, Czech Republic, France, Hungary, Israel, Italy, Japan, Netherlands, Republic of Korea, Romania, Spain

### NCT02323126
A Phase II, Multicenter, Open-label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive Non-small Cell Lung Cancer

**Cancer type:** Non-Small Cell Lung Cancer  
**Variant class:** MET positive  

**Other identifiers:** CEGF816X2201C, EudraCT Number: 2014-003731-20, TrialTroveID-218316  
**Population segments:** Adenocarcinoma, EGFR, Second line or greater/Refractory/Relapsed, Stage III, Stage IV  
**Phase:** II  
**Therapies:** capmatinib + nivolumab, EGF-816 + nivolumab  
**Country:** Singapore

---

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.
### NCT01610336
**A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment**

- **Cancer type:** Non-Small Cell Lung Cancer
- **Variant class:** MET amplification
- **Other identifiers:** CINC280X2202, CTR20132495, EudraCT Number: 2011-002569-39, TrialTroveID-169016
- **Population segments:** EGFR, Second line or greater/Refractory/Relapsed, Stage III, Stage IV
- **Phase:** I/II
- **Therapy:** capmatinib + gefitinib
- **Countries:** Australia, Belgium, China, France, Germany, Israel, Italy, Japan, Netherlands, Republic of Korea, Singapore, Spain, Taiwan, Thailand

### NCT01982955
**A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib**

- **Cancer type:** Glioblastoma, Non-Small Cell Lung Cancer
- **Variant class:** MET amplification
- **Other identifiers:** 200095-006, CTR20150252, EMR200095-006, TrialTroveID-197167
- **Population segments:** Adenocarcinoma, EGFR, Large Cell, Other subtype, Second line or greater/Refractory/Relapsed, Squamous Cell, Stage III, Stage IV
- **Phase:** I/II
- **Therapy:** gefitinib + tepotinib
- **Country:** Germany

### NCT01324479
**A Phase I Open-label Dose Escalation Study with Expansion to assess the Safety and Tolerance of INC280 in Patients with c-MET Dependent Advanced Solid Tumors**

- **Cancer Type:** BladderCancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, GIST, Glioblastoma, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Melanoma, Mesothelioma, Non-small cell Lung Cancer, Osteosarcoma, Pancreatic Cancer, Prostate Cancer, Skin Basal Cell Sarcoma, Small Cell Lung Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thyroid Cancer
- **Variant class:** MET amplification
- **Other identifiers:** 13-0171, 201104009MA, ACT004, CINC280X2102, EudraCT Number: 2010-024101-12, HKCCTR-1720, MDACC 2012-0985, NL43000.031.12, REFMAL 291 IST, TrialTroveID-144387
- **Population segments:** EGFR, HER2 negative, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative
- **Exclusion criteria variant class:** EGFR mutation
- **Phase:** I
- **Therapy:** capmatinib
- **Countries:** Australia, Canada, Germany, Hong Kong, Italy, Netherlands, Republic of Korea, Singapore, Spain, Taiwan, United States
- **US States:** IL, TN, TX
- **US Contact:** Novartis Pharmaceuticals [888-669-6682]
NCT01911507
Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Cancer type: Non-Small Cell Lung Cancer
Variant class: MET amplification
Other identifiers: CINC280XUS02T, TrialTroveID-191184, UCDCC#238

NCT00697632
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Variant class: MET amplification
Other identifiers: 00005540, 00009948, 20142263, 265-101, AAAP0559, DFCI 08-007, MGCD265-101, P1TMG265, Trial 101, TrialTroveID-081814
Population segments: Advanced, Bone mets, Hormone refractory, Liver mets, Second line or greater/Refractory/Relapsed, Stage II, Stage III, Stage IV, Unresectable Phase: I Therapy: MGCD-265 Countries: Canada, Republic of Korea, United States US States: CA, IL, MA, MO, NC, NY, PA, TX, UT, WA US Contact: Mirati Therapeutics Study Locator Services [844-356-0895; miratistudylocator@emergingmed.com]

NCT01391533
Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
Variant class: MET amplification
Other identifiers: EudraCT Number: 2010-021398-36, IEO S597/111, RECF2367, Sanofi TED11449 SARMET, SARMET, TED11449, TrialTroveID-149908, U1111-1117-9878
Population segments: Adenocarcinoma, Second line or greater/Refractory/Relapsed, Stage III, Stage IV Phase: I Therapy: SAR-125844 Countries: France, Italy, Spain, United States US State: MA US Contact: Clinical Sciences & Operations Sanofi-Aventis [Contact-Us@sanofi.com]

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.
### MET amplification (continued)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Cancer Type</th>
<th>Variant class</th>
<th>Other identifiers</th>
<th>Population segments</th>
<th>Exclusion criteria variant class</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01985555</td>
<td>I</td>
<td>Bladder Cancer, CRC, Esophageal Cancer, Gastric Cancer, GIST, Glioblastoma, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Melanoma, Mesothelioma, Non-Small Cell Lung Cancer, Osteosarcoma, Prostate Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Thyroid Cancer, Testicular Cancer.</td>
<td>MET amplification</td>
<td>2011-504-00CH1, TrialTroveID-188988</td>
<td>Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>NCT02374645</td>
<td>I</td>
<td>Non-Small Cell Lung Cancer</td>
<td>MET positive</td>
<td>CTR20140879, D5080C00001, TrialTroveID-253097</td>
<td>EGFR, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td>EGFR T790M mutation</td>
<td>China</td>
</tr>
<tr>
<td>NCT02219711</td>
<td>I</td>
<td>Head and Neck Cancer, Non-Small Cell Lung Cancer</td>
<td>MET aberration</td>
<td>516-00, AAAO0006, TrialTroveID-197300</td>
<td>Bone mets, Hormone refractory, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td></td>
<td>United States</td>
</tr>
</tbody>
</table>

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.
MET amplification (continued)

NCT01548144
A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies

Cancer type: Unspecified Cancer
Variant class: MET amplification

Other identifiers: 2011-1142, NCI-2012-00324, TrialTroveID-163762
Population segments: Second line or greater/Refractory/Relapsed, Stage IV
Phase: I
Therapies: crizotinib + chemotherapy, crizotinib + pazopanib, crizotinib + pazopanib + chemotherapy
Country: United States
US State: TX
US Contact: Dr Ralph Zinner [800-392-1611]

NCT01744652
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies

Cancer type: Unspecified Solid Tumor
Variant class: MET amplification

Other identifiers: 2012-0721, NCI-2013-00071, TrialTroveID-178941
Population segments: Aggressive, Classical, Hormone refractory, Indolent, Metastatic, Nodular lymphocyte-predominant, Second line or greater/Refractory/Relapsed, Stage IV, Unresectable
Phase: I
Therapy: crizotinib + dasatinib
Country: United States
US State: TX
US Contact: Dr. David S. Hong [800-392-1611]

NCT01657214
Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmaco-Dynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors

Cancer type: Unspecified Solid Tumor
Variant class: MET amplification

Other identifiers: SARMETA, TED12337, TrialTroveID-172382, U1111-1126-7527
Population segments: Second line or greater/Refractory/Relapsed, Stage III, Stage IV
Phase: I
Therapy: SAR-125844
Countries: Japan, Republic of Korea

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

www.oncologica.com

© 2016 Thermo Fisher Scientific. All rights reserved.
DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
NCT02228811
A Multicenter Phase IA/IB Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Cancer type: Unspecified Solid Tumor
Variant class: MET aberration
Other identifiers: 2014-0878, DCC-2701-01-001, TrialTroveID-201122, VICCPHI13113
Population segments: Second line or greater/Refractory/Relapsed, Stage III, Stage IV
Phase: I
Therapy: altiratinib
Country: United States
US States: CO, MA, PA, TN, TX
US Contact: Linda M. Martin [785-830-2100; lmartin@deciphera.com]

NCT02386826
Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer (mCRC) and Metastatic Renal Cell Carcinoma (mRCC) Patients
Cancer type: Colorectal Cancer, Glioblastoma, Kidney Cancer.
Variant class: MET amplification
Other identifiers: SCRI REFML 365, TrialTroveID-253602
Population segments: Second line or greater/Refractory/Relapsed, Stage IV Phase: I
Therapy: bevacizumab + capmatinib
Country: United States
US States: CO, TN
US Contact: Sarah Cannon Research Institute [877-691-7274; asksarah@scresearch.net]

NCT02510001
A Phase 1 Study of MEK 1/2 Inhibitor PD-0325901 With cMET Inhibitor PF-03241066 in RASMT and RASWT (With Aberrant c-MET) Colorectal Cancer Patients
Cancer type: Colorectal Cancer
Variant class: MET aberration
Other identifiers: 17363, EudraCT number: 2014-000463-40, ISRCTN18043777, MErCuRIC, MErCuRIC1, OCTO-049, TrialTroveID-217604, UKCRN ID:17363
Population segments: First line, Second line or greater/Refractory/Relapsed, Stage III, Stage IV
Phase: I
Therapy: crizotinib + PD-0325901
Countries: Belgium, Czech Republic, France, Ireland, Italy, Spain, United Kingdom
Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

**MET amplification (continued)**

**NCT02449551**
Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

**Cancer type:** Esophageal Cancer, Gastric Cancer.

**Variant class:** MET amplification

**Other identifiers:** 2014-07-167, TrialTroveID-257789

**Population segments:** Second line or greater/Refractory/Relapsed, Stage III, Stage IV

**Phase:** II

**Therapy:** volitinib

**Country:** Republic of Korea

---

**NCT02435108**
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

**Cancer type:** Esophageal Cancer, Gastric Cancer,

**Variant class:** MET positive

**Other identifiers:** 2014-03-117-003, TrialTroveID-257025

**Population segments:** Second line or greater/Refractory/Relapsed, Stage III, Stage IV

**Phase:** II

**Therapy:** crizotinib

**Country:** Republic of Korea

---

**NCT02447406**
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second-line Treatment

**Cancer type:** Esophageal Cancer, Gastric Cancer

**Variant class:** MET amplification

**Other identifiers:** 2014-07-169, TrialTroveID-257679

**Population segments:** Second line or greater/Refractory/Relapsed, Stage III, Stage IV

**Exclusion criteria variant class:** ERBB2 amplification

**Phase:** I/II

**Therapy:** volitinib + chemotherapy

**Country:** Republic of Korea

---

**No NCT ID - see other identifier(s)**
A Phase Ib, Efficacy Study of Savolitinib as a Monotherapy in c-Met Amplified Gastric Cancer Patients

**Cancer type:** Gastric Cancer

**Variant class:** MET amplification

**Other identifiers:** Study 9, TrialTroveID-263342

**Population segments:** (N/A), Line of therapy N/A

**Phase:** I

**Therapy:** volitinib

**Country:** China
### MET amplification (continued)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Description</th>
<th>Cancer Type</th>
<th>Variant Class</th>
<th>Other Identifiers</th>
<th>Population Segments</th>
<th>Phase</th>
<th>Therapy</th>
<th>Countries</th>
<th>US States</th>
<th>US Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>No NCT ID - see other identifier(s)</td>
<td>A Phase Ib, Dose Finding Study of Savolitinib in Combination with Docetaxel in c-Met Amplified, First Line Gastric Cancer Patients</td>
<td>Gastric Cancer</td>
<td>MET amplification</td>
<td>Study 11, TrialTroveID-263335</td>
<td>(N/A), First line</td>
<td>I</td>
<td>volitinib + chemotherapy</td>
<td>China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01870726</td>
<td>A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 or in Combination With Buparlisib in Patients With Recurrent Glioblastoma</td>
<td>Glioblastoma</td>
<td>MET amplification</td>
<td>13-501, 2013-0632, AAAM3463, CINC280X2204, EudraCT Number: 2013-000699-14, NL45781.041.13, Novartis INC280, RReEC-2013-0630, SAKK 66/13, TrialTroveID-188051</td>
<td>(N/A), Second line or greater/Refractory/Relapsed</td>
<td>I/II</td>
<td>buparlisib + capmatinib</td>
<td>Germany, Netherlands, Spain, Switzerland, United States</td>
<td>NC, NY, TX</td>
<td>Novartis Pharmaceuticals [888-669-6682]</td>
</tr>
</tbody>
</table>

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Description</th>
<th>Other identifiers</th>
<th>Population segments</th>
<th>Phase</th>
<th>Therapies</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02323126</td>
<td>A Phase II, Multicenter, Open-label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive Non-small Cell Lung Cancer</td>
<td>CEGF816X2201C, EudraCT Number: 2014-003731-20, TrialTroveID-218316</td>
<td>Adenocarcinoma, EGFR, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td>II</td>
<td>capmatinib + nivolumab, EGF-816 + nivolumab</td>
<td>Singapore</td>
</tr>
<tr>
<td>NCT00697632</td>
<td>Open-Label Dose-escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies</td>
<td>00005540, 00009948, 20142263, 265-101, AAAP0559, DFCI 08-007, MGCD265-101, P1TMG265, Trial 101, TrialTroveID-081814</td>
<td>Advanced, Bone mets, Hormone refractory, Liver mets, Second line or greater/Refractory/Relapsed, Stage II, Stage III, Stage IV, Unresectable</td>
<td>I</td>
<td>MGCD-265</td>
<td>Canada, Republic of Korea, United States</td>
</tr>
<tr>
<td>NCT02510001</td>
<td>A Phase 1 Study of MEK 1/2 Inhibitor PD-0325901 With cMET Inhibitor PF-03241066 in RASMT and RAS WT (With Aberrant c-MET) Colorectal Cancer Patients</td>
<td>17363, EudraCT number: 2014-000463-40, ISRCTN18043777, MERCuRIC, MERCuRIC1, OCTO-049, TrialTroveID-217604, UKCRN ID:17363</td>
<td>First line, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
<td>I</td>
<td>crizotinib + PD-0325901</td>
<td>Belgium, Czech Republic, France, Ireland, Italy, Spain, United Kingdom</td>
</tr>
</tbody>
</table>

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.
DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### MET-MET fusion (continued)

<table>
<thead>
<tr>
<th>NCT02374645</th>
<th>Other identifiers: CTR20140879, D5080C00001, TrialTroveID-253097</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment</td>
<td><strong>Population segments</strong>: EGFR, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
</tr>
<tr>
<td><strong>Exclusion criteria variant class</strong>: EGFR T790M mutation</td>
<td><strong>Phase</strong>: I</td>
</tr>
<tr>
<td><strong>Therapy</strong>: gefitinib + volitinib</td>
<td><strong>Country</strong>: China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02219711</th>
<th>Other identifiers: 516-00, AAAO0006, TrialTroveID-197300</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase I/Ib Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies</td>
<td><strong>Population segments</strong>: Bone mets, Hormone refractory, Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
</tr>
<tr>
<td><strong>Phase</strong>: I</td>
<td><strong>Therapy</strong>: MGCD-516</td>
</tr>
<tr>
<td><strong>Country</strong>: United States</td>
<td><strong>US States</strong>: MA, MO, NY, TN, UT</td>
</tr>
<tr>
<td><strong>US Contact</strong>: Mirati Therapeutics Study Locator Services [844-356-0895; <a href="mailto:miratistudylocator@emergingmed.com">miratistudylocator@emergingmed.com</a>]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02228811</th>
<th>Other identifiers: 2014-0878, DCC-2701-01-001, TrialTroveID-201122, VICCPI13113</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Multicenter Phase Ia/IB Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors</td>
<td><strong>Population segments</strong>: Second line or greater/Refractory/Relapsed, Stage III, Stage IV</td>
</tr>
<tr>
<td><strong>Phase</strong>: I</td>
<td><strong>Therapy</strong>: altiratinib</td>
</tr>
<tr>
<td><strong>Country</strong>: United States</td>
<td><strong>US States</strong>: CO, MA, PA, TN, TX</td>
</tr>
<tr>
<td><strong>US Contact</strong>: Linda M. Martin [785-830-2100; <a href="mailto:lmartin@deciphera.com">lmartin@deciphera.com</a>]</td>
<td></td>
</tr>
</tbody>
</table>

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.

DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
### Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

---

#### MET-MET fusion (continued)

| NCT02435108 | **A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy**  
**Cancer type:** Esophageal Cancer, Gastric Cancer  
**Variant class:** MET positive  
**Other identifiers:** 2014-03-117-003, TrialTroveID-257025  
**Population segments:** Second line or greater/Refractory/Relapsed, Stage III, Stage IV  
**Phase:** II  
**Therapy:** crizotinib  
**Country:** Republic of Korea |

| NCT01870726 | **A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 or in Combination With Buparlisib in Patients With Recurrent Glioblastoma**  
**Cancer type:** Glioblastoma  
**Variant class:** MET fusion  
**Other identifiers:** 13-501, 2013-0632, AAAM3463, CINC280X2204, Eudract Number: 2013-000699-14, NL45781.041.13, Novartis INC280, REec-2013-0630, SAKK 66/13, TrialTroveID-188051  
**Population segments:** (N/A), Second line or greater/Refractory/Relapsed  
**Phase:** I/II  
**Therapy:** buparlisib + capmatinib  
**Countries:** Germany, Netherlands, Spain, Switzerland, United States  
**US States:** NC, NY, TX  
**US Contact:** Novartis Pharmaceuticals [888-669-6682] |
CDK6 amplification

**NCT02154490**  
S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer  
Cancer type: Non-Small Cell Lung Cancer  
Variant class: CDK6 amplification


Population segments: FGFR, Second line or greater/Refractory/Relapsed, Squamous Cell, Stage III, Stage IV

Exclusion criteria variant classes: ALK fusion, EGFR mutation

Phase: II/III

Therapies: AZD4547 + chemotherapy, durvalumab, erlotinib, erlotinib + rilotumumab, palbociclib, taselisib

Country: United States

US States: AR, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MT, NC, ND, NE, NH, NJ, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

**NCT02187783**  
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 8 - LEE011 for Patients with CDK4/6 Pathway Activated Tumors  
Variant class: CDK6 amplification

Other identifiers: 051501, 2014-0689, CLEE011XUS03, SIGNATURE, TrialTroveID-212878

Population segments: Aggressive, Cutaneous T-cell lymphoma (CTCL), Diffuse large B-cell lymphoma (DLBCL), Extranodal marginal zone B-cell lymphoma (MALT), Follicular lymphoma (FL), HER2 negative, Indolent, Lymphoblastic lymphoma (LBL), Other subtype, Peripheral T-cell lymphoma (PTCL), Second line or greater/Refractory/Relapsed, Small lymphocytic lymphoma (SLL), Stage III, Stage IV, Triple receptor negative, Waldenstrom’s macroglobulinemia (WM)

Phase: II

Therapy: ribociclib

Country: United States

US States: AK, AZ, CA, CT, GA, IN, LA, MD, MO, NC, NM, OH, OR, RI, SD, TN, TX, UT, VA, WA, WI

US Contact: Multiple contacts: See www.clinicaltrials.gov for complete list of contacts.

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

© 2016 Thermo Fisher Scientific. All rights reserved.  
DISCLAIMER: The data presented here is a result of the curation of published data sources, but may not be exhaustive. The data version is 2016.02(002).
6. Liability

6.1 Oncologica operates in compliance with international ISO15189:2012 standards and is regulated by UKAS. The Oncologica Tests have not been cleared or approved by the United States Food and Drug Administration; however, such clearance or approval is not required.

6.2 The Patient agrees that the Oncologica Test Report is intended for clinical use and interpretation by a physician who is experienced and skilled in the use and interpretation of clinical test data. The Oncologica Test Report is based on the Sample submitted by the Patient. The Oncologica Test Report should not be considered or its contents applied to any other patient or any other sample. Oncologica does not update an Oncologica Test Report once it has been sent.

6.3 Information compiled in the Oncologica Test Report includes is from publicly available as well as proprietary sources. By updating the source database, Oncologica makes every effort to provide the most accurate and up-to-date information. However, Oncologica does not warrant or represent that the information in the Oncologica Test Report is accurate, timely or complete.

6.4 The Oncologica Test Report contains drug and clinical trial information. However, Oncologica does not warrant or represent that any drug or clinical trial identified by the Oncologica Test will guarantee a therapeutic response for a particular Patient. The drugs listed in an Oncologica Test Report are ranked on clinical evidence as to the predicted efficacy or appropriateness for the Patient. The Patient shall ensure that its physician shall evaluate and interpret the Oncologica Test Report, along with all other available clinical information about the Patient, to determine the best treatment decisions in their own independent medical judgment. Patient management decisions should not be based on a single test, nor solely on the information contained in the Oncologica Test Report.

6.5 Subject to paragraph 6.10, Oncologica shall have no liability for any use made of the information provided in the Oncologica Test Report, including but not limited to any report prepared by Oncologica summarising the results of the Oncologica Tests, any advice supplied by Oncologica, any decisions taken, or for any costs incurred by Patient and/or the Patient’s physician and/or the Agent in consequence of such use, advice or decisions. The Oncologica Test and/or the Oncologica Test Report is not a substitute for the Patient’s physician’s professional judgment. The use of the information provided in the Oncologica Test Report is provided as a tool for the ordering physician’s use in determining the appropriate treatment for the Patient. The decision as to what course of treatment and the appropriate use of the information provided by the Oncologica Test Report is solely that of the Patient's physician.

6.6 Oncologica does not warrant or represent that the Oncologica Tests will identify an actionable genetic alteration that is linked to anti-cancer targeted therapies. Although the Oncologica Tests are comprehensive, in a proportion of Patients, the Oncologica Test result may not identify any actionable mutations for a patient’s cancer. In the event that no actionable alteration in the Sample is identified by the Oncologica Test, then the Patient is still under full obligation to pay the Charges and no refund is available to the Patient and/or Agent.

6.7 The Oncologica Test identifies genomic actionable alterations found in the submitted Sample that are linked to anti-cancer targeted agents. Also note that this test only examines tumour, and not normal tissue from the patient, and therefore cannot distinguish between somatic and germline (i.e., heritable) alterations.

6.8 Subject to Clause 6.8, Oncologica shall not be liable to the Patient whether in contract, tort (including negligence and breach of statutory duty), or otherwise for any:

(a) Error or defect in the Oncologica Test Report as a result of any inaccurate or incomplete information supplied by the Patient;

(b) Loss of data or materials, including the Sample and/or the Report and including any loss arising as a result of the acts or omissions of a courier;

(c) Indirect or consequential loss arising whether or not advised of the possibility of the same.

6.9 Subject to the provisions of this Clause 6, Oncologica’s total liability to the Patient in respect of all losses arising under or in connection with the Contract, whether in contract, tort (including negligence and breach of statutory duty), or otherwise, shall in no circumstances exceed the Charges paid for the Test that is the subject of the claim.

6.10 Nothing in the Contract limits or excludes the liability of Oncologica for breach of its obligations under section 12 of the Sale of Goods Act 1979 and/or section 2 of the Supply of Goods and Services Act 1982; death or personal injury resulting from negligence; or fraud or fraudulent misrepresentation.

6.11 If the Patient is a consumer (and not a business), the Patient expressly acknowledges and agrees that the Test is supplied to the Patient’s specification and therefore there is no right to cancel the Test following acceptance under Clause 2.2. If the Patient is a consumer, then notwithstanding any other provisions of the Contract, none of the Patient’s consumer statutory rights are affected.